Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA review details suicides, cardio risks linked to Valeant’s $100M drug brodalumab
FDA review details suicides, cardio risks linked to Valeant’s $100M drug brodalumab
FDA review details suicides, cardio risks linked to Valeant’s $100M drug brodalumab
Submitted by
admin
on July 15, 2016 - 10:27am
Source:
Endpoints
News Tags:
FDA
Valeant Pharmaceuticals
suicide
brodalumab
psoriasis
Headline:
FDA review details suicides, cardio risks linked to Valeant’s $100M drug brodalumab
Do Not Allow Advertisers to Use My Personal information
